Neurological & Neuromuscular
Also called LGS, Petit Mal Variant
Lennox-Gastaut Syndrome represents one of the most severe and intractable childhood epilepsies, often emerging from or following infantile spasms (West Syndrome). The characteristic EEG pattern shows slow (1-2.
Lennox-Gastaut Syndrome typically manifests between ages 1 and 8 years, with peak onset between 3 and 5 years. It affects males and females equally and occurs across all ethnic and racial groups. While some cases are symptomatic (caused by identified brain abnormalities), many are cryptogenic or idiopathic with no clear underlying cause. Previous history of infantile spasms increases risk.
Treatment of Lennox-Gastaut Syndrome remains challenging, but recent FDA approvals of medications like cannabidiol and topiramate have improved outcomes. Clinical trials continue investigating novel antiepileptic drugs, gene therapy approaches, and neuromodulation strategies. Vagus nerve stimulation and ketogenic diet therapy represent non-pharmacological options with documented benefit. Specialized epilepsy centers can provide comprehensive evaluation and information about available trials. The Epilepsy Foundation and Lennox-Gastaut Syndrome specific organizations maintain updated trial registries.
Duchenne muscular dystrophy is an X-linked genetic disorder causing progressive muscle weakness and degeneration, beginn...
Spinal muscular atrophy is an autosomal recessive genetic disorder affecting motor neurons in the spinal cord, causing p...
Myasthenia gravis is a chronic autoimmune neuromuscular disorder causing muscle weakness and rapid fatigue. Antibodies a...